Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Holdings Trimmed by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lessened its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 23.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 187,414 shares of the company’s stock after selling 58,558 shares during the period. Allspring Global Investments Holdings LLC owned about 0.57% of Tarsus Pharmaceuticals worth $3,795,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in TARS. Dimensional Fund Advisors LP boosted its holdings in Tarsus Pharmaceuticals by 221.0% in the first quarter. Dimensional Fund Advisors LP now owns 28,855 shares of the company’s stock worth $485,000 after purchasing an additional 19,865 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Tarsus Pharmaceuticals by 3.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 48,583 shares of the company’s stock valued at $818,000 after buying an additional 1,402 shares during the last quarter. UBS Group AG raised its stake in Tarsus Pharmaceuticals by 37.0% during the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock worth $71,000 after acquiring an additional 1,142 shares during the period. Invesco Ltd. lifted its holdings in Tarsus Pharmaceuticals by 17.1% in the first quarter. Invesco Ltd. now owns 27,982 shares of the company’s stock worth $471,000 after acquiring an additional 4,078 shares during the last quarter. Finally, State Street Corp raised its position in shares of Tarsus Pharmaceuticals by 2.4% during the 1st quarter. State Street Corp now owns 132,883 shares of the company’s stock worth $2,235,000 after purchasing an additional 3,141 shares during the period. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $32.44 on Friday. Tarsus Pharmaceuticals, Inc. has a twelve month low of $12.57 and a twelve month high of $40.40. The company has a quick ratio of 6.85, a current ratio of 6.93 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average of $33.83 and a 200-day moving average of $24.33.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.06. The firm had revenue of $13.08 million during the quarter, compared to analyst estimates of $4.63 million. During the same quarter last year, the company earned ($0.49) earnings per share. On average, research analysts expect that Tarsus Pharmaceuticals, Inc. will post -4.25 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on TARS shares. The Goldman Sachs Group boosted their price objective on Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the company a “neutral” rating in a research report on Thursday, February 29th. Jefferies Financial Group increased their price objective on shares of Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Oppenheimer reissued an “outperform” rating and set a $59.00 target price (up from $55.00) on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 28th. HC Wainwright raised their price target on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Finally, Lifesci Capital reissued an “outperform” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, December 26th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $48.38.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 4,436 shares of the business’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $135,741.60. Following the sale, the general counsel now directly owns 40,951 shares in the company, valued at $1,253,100.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 4,436 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $135,741.60. Following the transaction, the general counsel now owns 40,951 shares in the company, valued at $1,253,100.60. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Bobak R. Azamian sold 10,415 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $318,699.00. Following the completion of the transaction, the chief executive officer now directly owns 26,456 shares in the company, valued at approximately $809,553.60. The disclosure for this sale can be found here. Insiders sold 24,496 shares of company stock valued at $749,578 over the last 90 days. 11.54% of the stock is currently owned by corporate insiders.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.